{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-086131","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.555130+00:00","generated_at":"2026-06-24T03:51:27.202464+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Protagonist Q2 net loss $41M; rusfertide Phase 3 enrollment slower, cash runway to end 2024","bullets":["Net loss of $41.0M ($0.84 per share) vs $30.8M loss in Q2 2021; license revenue $0.9M.","Cash and equivalents $291.9M, expected to fund operations through end of 2024.","Phase 3 VERIFY study enrollment slower than anticipated; target to complete enrollment by end of first half 2023.","Janssen (PN-235) advancing Phase 2b psoriasis studies; $10M milestone for second indication Phase 2 start, $50M for Phase 3 dosing.","PN-943 seeking FDA guidance for Phase 3 and partnership; IDEAL study results to be presented at UEGW Oct 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-086131","json":"https://secwatch.observer/filing/0001104659-22-086131.json","markdown":"https://secwatch.observer/filing/0001104659-22-086131.md","text":"https://secwatch.observer/filing/0001104659-22-086131.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922086131/0001104659-22-086131-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922086131/tm2222452d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T03:51:27.202464+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}